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Executive Summary 
  Antimicrobial resistant organisms are a growing threat in the United States and globally. 
It has become the expectation that healthcare institutions, including hospitals, contribute 
resources to create and maintain antimicrobial stewardship programs to decrease antimicrobial 
resistance, improve patient outcomes, and decrease the spread of multi-drug resistant organisms. 
The methods utilized to evaluate antimicrobial stewardship at hospitals often only evaluate 
outcome measures and fail to capture knowledge of the hospital antimicrobial stewardship 
program among prescribers, clinical pharmacists, and nurses, as well potential barriers to 
antimicrobial stewardship among healthcare providers. The purpose of this Doctor of Nursing 
project is to implement and evaluate the use of tracer methodology to evaluate both 
implementation and outcomes of a hospital antimicrobial stewardship program. For this project, 
a tracer was designed by a multidisciplinary team to evaluate treatment of community acquired 
pneumonia at a local 130-bed regional trauma center affiliated with a large regional not-for-
profit health system. The hospital was motivated to conduct the evaluation in response to a 
suggestion from a state government agency active in promoting hospital ASPs. The results of 
this evaluation suggest that successful implementation of a tracer is reliant on the quality of 
questions, the abilities of the surveyor, response from participants, and recognition that 
antimicrobial stewardship is multifaceted. Further, the interpretation of tracer questions is not 
always straightforward and tracer results should be interpreted as such. When possible, tracer 
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Utilizing Tracer Methodology to Evaluate the Effectiveness of a Hospital Antimicrobial 
Stewardship Program 
Introduction 
Antimicrobial resistance of microorganisms, including bacteria and fungi, is a growing 
threat globally and in the United States (Centers for Disease Control [CDC], 2020; World Health 
Organization [WHO], 2018). In 2013 the CDC estimated at least 23,000 people die each year 
from antibiotic-resistant infections and more than two million people are infected with antibiotic-
resistant organisms (CDC, 2013). The data released by the CDC in 2013 held the caveat that the 
available numbers were likely underestimated due to limitations in data collection (CDC, 2013). 
The CDC revised the estimates from 2013 using updated methodologies and data resources and 
these revised estimates indicated that when the 2013 report was published, more than 2.6 million 
antibiotic-resistant infections and 44,000 deaths occurred (CDC, 2019a). The most recent data 
released in 2019 reports more than 2.8 million antibiotic-resistant infections occur each year in 
the United States and more than 35,000 people die from such infections (CDC, 2019a). However, 
when comparing the newly recalculated data from 2013 to the newest available data in 2019, the 
CDC found that deaths from antibiotic-resistant infections had decreased by 18 percent thanks to 
actions implemented through the National Action Plan for Combating Antibiotic-Resistant 
Bacteria (CARB) (CDC, 2019a). A decrease in deaths is encouraging, however, antibiotic 
resistance remains a threat due to the ability of microorganisms to constantly adapt and develop 
mechanisms of resistance to antibiotics (WHO, 2018).  
The development of resistance to antibiotics by microorganisms is evolutionarily 
inevitable, however, when antibiotics are frequently present in the environment or a host, the 
development of resistance is accelerated (CDC, 2020; WHO 2018). Inappropriate use of 
antibiotics includes administration of antibiotics that are not necessary, not the optimal antibiotic, 
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or the incorrect dose and duration of an antibiotic (CDC, 2019b). The CDC has concluded that 
20-50% of antibiotics prescribed in acute care hospitals are unnecessary or inappropriate. 
Furthermore, researchers at the CDC found that the rate at which healthcare providers prescribe 
antibiotics varies widely among hospitals, with some providers prescribing three times as many 
antibiotics when compared to providers in similar departments of other hospitals (CDC, 2019c). 
Also of note, Baggs, Fridkin, and Pollack (2016) found that while the overall rate of antibiotic 
use in hospitals did not change from 2006 to 2012, changes were noted in the types of antibiotics 
being prescribed. The researchers found that the use of carbapenems increased by 37 percent and 
the use of vancomycin increased by 32 percent.  Thus, decreases in the use of fluroquinolones 
and first- and second- generation cephalosporins were offset by the significant increases in 
vancomycin and agents with broad-spectrum activity against gram-negative bacteria. 
Antimicrobial stewardship programs (ASPs) are coordinated efforts which promote the 
appropriate use of antimicrobials within various settings. The goals of ASPs are to improve 
patient outcomes, decrease antimicrobial resistance, and decrease the spread of infections caused 
by multi-drug resistant organisms (MDROs) (Association for Professionals in Infection Control 
and Epidemiology [APIC], n.d.). Hospital-based ASPs have been shown to effectively reduce 
inappropriate use of antibiotics, thereby reducing rates of Clostridium difficile, antibiotic 
resistance, and side effects related to antibiotics (CDC, 2019c). In 2014 the CDC released the 
Core Elements of Hospital Antibiotic Stewardship Programs providing the basis for hospitals to 
establish and improve stewardship programs. The seven core elements: (a) Leadership 
Commitment, (b) Accountability, (c) Pharmacy Expertise, (d) Action, (e) Tracking, (f) 
Reporting, and (g) Education are meant to serve as a framework for hospitals by supplying the 
structural and procedural components necessary for a stewardship program. Five years later, the 
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CDC has released an updated version of the Core Elements of Hospital Antibiotic Stewardship 
Programs that is based on new evidence pertaining to antibiotic stewardship and information 
gathered since 2014. The seven core elements remain the same though each includes updates to 
incorporate new evidence from the field of antibiotic stewardship and lessons learned from the 
past five years. The structure of ASPs remain the decision of each individual hospital or 
healthcare system based on the size, type, and available resources, but programs are expected to 
integrate components from all seven core elements (CDC, 2019d).  
The Joint Commission (TJC) and the Det Norske Veritas-Germanischer Lloyd (DNV-
GL) use the Core Elements as the basis for accreditation standards (DNV-GL, 2019). 
Additionally, the 2019 revision of the hospital conditions of participation from the Centers for 
Medicare and Medicaid Services (CMS) created a federal regulation for hospital ASPs and 
references the Core Elements (Centers for Medicare and Medicaid Services [CMS], 2019). As of 
2018, 85% of acute care hospitals in the United States report implementing all seven CDC Core 
Elements (CDC, 2019d). On January 1, 2017 TJC released a new antimicrobial stewardship 
standard applicable to hospitals and critical access hospitals (TJC, 2016; TJC, 2017). One 
method utilized by TJC to assess compliance with accreditation standards is tracer methodology, 
however, such a method has not yet been utilized to assess hospital ASPs. Tracers can provide 
organizations with useful feedback by either validating practices or identifying knowledge gaps 
or deviations from evidence-based practices and guidelines. This project applied tracer 
methodology with the goal of evaluating the success of a hospital ASP, identifying potential gaps 
in knowledge or deviations from evidence-based practices, and verifying the fulfillment of 
accreditation requirements.   
 




A 130-bed regional trauma center affiliated with a large regional not-for-profit health 
system required evaluation of an active ASP (see Appendix A for Letter of Support from 
Agency). Once hospitals implement an ASP, ongoing assessment is necessary to ensure 
interventions are effective and to provide hospital leadership and healthcare providers with 
feedback. Assessing ASPs provides program leaders with the opportunity to identify potential 
gaps or deviations from evidence-based practices and the obstacles related to antibiotic 
stewardship healthcare providers encounter. Previous interventions implemented by the hospital 
stewardship team included the following: (a) audit and feedback; (b) provision of a hospital 
antibiogram to clinicians, (c) educational presentations regarding clinical guidelines and 
antibiotic prescribing, (d) encouragement to conduct antibiotic “timeouts”, (e) formulary 
restrictions, and (f) implementation of specific diagnostic testing for patients being treated with 
specific antibiotics for certain diagnoses.  
Tracking and reporting antibiotic prescribing and outcomes such as C. difficile and 
resistance patterns provides valuable feedback, however, understanding the ways in which 
providers prescribe antibiotics and the factors that influence their actions helps program leaders 
to design and modify programs that support providers in their stewardship practices. Past 
evaluation methods at the hospital did not attempt to specifically identify processes and barriers 
related to antimicrobial prescribing. Determining the feasibility of applying tracer methodology 
to evaluate a hospital ASP came to focus when an ASP physician lead proposed the intervention, 
and a state government agency proposed using tracer methodology to evaluate hospital ASPs.  
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The hospital employs 42 hospitalists on staff who provide care coverage for six different 
units during twelve-hour shifts. When patients are admitted through the emergency department 
(ED), orders are initiated by the ED physician who provides a handoff report to the internal 
medicine hospitalist. The hospitalist reviews the orders placed for the patient and makes changes 
as necessary. Each unit of the hospital is assigned a clinical pharmacist during the day who 
reviews patient medications. Rounds on select patients are led each morning by the hospitalist 
and are attended by the clinical pharmacist, nurses, and case managers. During rounds the status 
of the patient is discussed with regards to plan of care, including nursing care, medications, and 
preparations necessary for discharge.   
The ASP team had nine members: (a) an antimicrobial stewardship physician lead; (b) an 
antimicrobial stewardship pharmacist lead; (c) an infectious disease specialist; (d) the 
microbiology lab director; (e) the hospital lab director; (f) the pharmacy director; (g) a 
hospitalist; (h) and infection preventionist; (i) and an administrator. To evaluate current 
prescribing practices and identify potential barriers to antimicrobial stewardship, the 
antimicrobial stewardship physician lead team proposed implementing tracer methodology to 
specifically evaluate treatment of community acquired pneumonia (CAP) and general knowledge 
of antibiotic stewardship among physicians, clinical pharmacists, and nurses.  
Available Knowledge 
PICOT 
 With the intent of creating and implementing a tracer to evaluate a hospital ASP and the 
impact of the program on the knowledge and practices of staff, a review of the literature was 
conducted to search for evidence supporting best practices. A PICOT question guided the search. 
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The components of a PICOT question are: patient population, intervention, comparison, 
outcome, and time (University of North Carolina, 2019). 
Is conducting a tracer in an acute care hospital, from February 2020 to July 2020, an 
effective method for evaluating a hospital-based ASP with regards to the treatment of CAP when 
compared to only using process measures?  
Search Methodology  
A systematic review of the literature was conducted in the PUBMED and CINHAL 
databases between December 2019 and April 2020. The search criteria included full text, peer 
reviewed articles in English from 2010 to 2020 using the following search terms in various 
forms: tracer method*, antibiotic, and antimicrobial. The search yielded a total of 454 articles, 
including duplicates. Articles were selected if tracer methodology was proposed or implemented 
to evaluate a program addressing a clinical need within an acute care or outpatient setting. 
Articles were appraised using the John Hopkins Research Evidence Appraisal Tool (see 
Appendix B) (Johns Hopkins Hospital, 2017). 
Literature Review 
ASP evaluation methods. Previous methods utilized to assess ASPs include 
interventional, retrospective, and ecological studies to evaluate economic outcomes, clinical 
outcomes, microbial and resistance outcomes, and process measures (Aldeyab et al., 2012; 
McGregor & Furuno, 2014). Clinical outcomes include hospital length of stay (LOS), mortality, 
clinical cure or failure, readmission rates, and adverse events associated with antimicrobial 
therapy. Assessing microbial or resistance outcomes involves measuring the incidence or 
prevalence of colonization or infection by an organism at the individual or population level. 
Process measures data include antimicrobial days of therapy, however, such measures should be 
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validated in order to establish an association with clinical outcomes (McGregor & Furuno, 
2014). To assess progress and barriers to ASPs, surveys, and questionnaires have been 
administered (Van Limburg, Sinha, Lo-Ten-Foe, & Gemert-Pijnen, 2014). In a review of the 
literature, Hulscher and Prins (2017) concluded that antimicrobial stewardship teams face the 
challenge of selecting change interventions based on assessment of barriers, facilitators, and 
determinants of change interventions, especially since large differences in improvement were 
noted between studies that tested similar change interventions.  
Description of tracers. Three types of tracer methods exist; individual tracers, systems 
tracers, and accreditation program-specific tracers (TJC, 2018). Individual tracers examine 
patient care experiences while at an organization by evaluating the provision of care and 
treatment within an institution. In individual tracers, patients are the framework used to 
determine compliance with set standards. Systems tracers aid in evaluating an entire system or 
process, including the way related processes are incorporated and the way different departments 
and disciplines coordinate and communicate within the system or process. Systems tracers are 
used to evaluate data management, infection control, and medication management. Accreditation 
program-specific tracers help to identify risks and safety concerns at different levels of care, 
treatment, and services, especially regarding issues specific to the organization (TJC, 2018).  
When TJC conducts a tracer, it generally involves speaking with multiple staff members, 
patients, and family to learn details about each healthcare experience. Surveyors are collecting 
information to evaluate compliance with National Patient Safety Goals; adherence to policies and 
procedures; staff competency; communication within and between departments, programs, and 
services; and the physical environment as it relates to safety. Commonly, tracers start at the point 
of sample collection, critical results, transfusions, point of care testing, or frozen sections. 
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Surveyors review items such as orders, policies and procedures, employee competency, blood 
utilization review, process improvement, patient medical records, and instrument maintenance 
records. They also observe staff and conduct staff interviews (Olea, Paiano, & Olson, n.d.). 
A search of the literature revealed studies in which tracer methodology was applied to 
novel applications, however, the application of tracer methodology to evaluate ASPs was not 
among these applications. Tracer methodology has been suggested or applied to assess a variety 
of other clinical and patient care practices including surgical site infections, pain reassessment 
standards, infection control standards, outpatient mental health services, and end-of-life care 
(Bailey et al., 2015; Bookbinder et al., 2015; Padgette & Wood, 2018; Ross, Feider, Nahm, & 
Staggers, 2017; Wisdom et al., 2012). Padgette and Wood (2018) recognize tracer methodology 
can be adapted and applied to all areas of inpatient and ambulatory healthcare at the individual or 
system level. Additionally, Bookbinder et al. (2018) suggest tracer methodology may be adapted 
to routine quality improvement activities when implemented in different settings, proposing the 
integration of the tracer into the normal work of a unit with a simple audit tool to guide 
information gathering.  
A mock tracer is a simulation of an actual tracer. Developing a mock tracer requires four 
primary steps: planning, conducting, analyzing, and applying (TJC, 2011). To develop and 
implement a tracer, TJC recommends a series of steps and methods within the steps. The studies 
that utilized tracer methodology all had similar implementation approaches which closely 
followed the steps and methods recommended by TJC. An integrative discussion of the literature 
review will be discussed according to the steps proposed by TJC. 
Planning for tracer methodology. According to TJC (2011) the planning stage involves 
establishing a schedule, determining the scope of the tracer, identifying surveyors, and training 
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the surveyors. Padgette and Wood (2018) highlight the importance of involving a 
multidisciplinary team in the planning phase as each member can offer insight and has an interest 
in the practice being traced. For example, to plan for a tracer evaluating the quality of end-of-life 
care, Bookbinder et al. (2015) generated a large pool of questions related to processes and 
outcomes of quality of end-of-life care. The authors then collected the questions into three 
separate instruments to use in a prospective survey of care provided to patients who died in the 
hospital. A committee of members from hospital administration, medicine, nursing, social work, 
ethics, chaplaincy, and education was established to write questions. Questions were based on 
literature describing the best practices in palliative care, and the process was described as 
iterative. Similarly, to assess mental health services, Wisdom et al. (2012) worked with clinicians 
and administrators to create 31 measurable criteria and examples from standards of care to 
design a licensing instrument. Ross et al. (2017) also created a multidisciplinary team from 
different departments and specialties, including primary care, nursing, quality management, and 
information technology to evaluate pain reassessment processes in a primary care clinic. The 
process included a review of the electronic medical record (EMR), observation of clinic 
workflow, and evaluation of clinic documentation and workflow.  
Conducting a mock tracer. To conduct a mock tracer, TJC (2011) suggests teams 
consider several options when assigning the role of surveyor. Teams can consider a surveyor 
who is an expert in an area similar to the department, program, or service being assessed, but 
caution teams not to assign surveyors to the same area they work, in order to ensure objectivity. 
Alternatively, a team can choose to assign a surveyor with no experience in the area, but then 
must be sure to provide enough time for the surveyor to prepare and become familiar with the 
requirements. Pairing surveyors is another option as it allows surveyors to learn from each other. 
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Prior to conducting the tracer, the department, program, or service within the organization should 
be notified of the possibility of the mock tracer. When the tracer is commenced surveyors will 
collect data by taking notes of observations, conversations, and review of documents. Surveyors 
should be methodical and detail oriented, remind interviewees of the purpose of the tracer, 
maintain focus, but also remain flexible and productive. It is also advised that the surveyor is 
prepared to address any problems with the tracer that may be identified during the survey, 
including logistical issues, staff cooperation, and time involved. Once each tracer is completed, 
especially the first few tracers, it is recommended the team meets to debrief about the tracer 
process by allowing each team member to share and discuss issues they encounter.  
To assess end-of-life care, Bookbinder et al. (2015) conducted a survey that included a 
review of the medical record and interviews with physicians, nurses, social workers, and 
chaplains who provided care in the 48 hours prior to the patient’s death. The data was then 
analyzed to determine which questions could be used in a smaller survey, but still capture the 
more detailed information obtained when the three instruments were used. Next, a field test was 
conducted to determine if a clinician-led tracer could effectively be used to assess end-of-life 
care. Prior to the field-test, the nurse manager of a palliative care unit was trained by the survey 
creators in tracer methodology, specifically regarding obtaining information from front-line 
clinicians and the chart used to rate survey items.  
In an assessment of mental health services, Wisdom et al. (2012) implemented a toolkit 
which included documents associated with the licensing process, video presentations related to 
standards of care and implementing best practices, a question and answer page to address topics 
raised by providers and other stakeholders, and an email address for questions, suggestions, 
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issues, and comments. Protocols were in place to select tracer cases, and field tests were 
conducted by central office and field office staff.  
To evaluate pain reassessment processes, Ross et al. (2017) reviewed the EMR of 
patients who received Toradol, then utilized tracer methodology to track patients’ process 
through clinic workflow and noted compliance for the same pain reassessment requirements as 
was reviewed in the EMR. A workflow questionnaire was also administered to capture the pain 
reassessment process and clinic procedures for clinic staff. With regards to patient selection, 
authors Padgette and Wood (2018) state that selections of patients can be random or targeted 
based on the tracer goal, but note it is important to ensure the number and type of patients 
observed allow for adequate validation of the practices or processes being evaluated. However, 
in the study conducted by Ross et al. (2017) the tracer sample size was purposely small in order 
to allow comprehensive evaluation of pain reassessment practices during observations. Though 
the authors acknowledge, the small sample size limits the generalizability of the findings.  
Analyzing tracer data. Organizing and analyzing the data collected from the mock 
tracer is important in order to review, rank, and prioritize the problems and issues uncovered. 
TJC recommends several methods for organizing data, including developing a method to 
categorize the completed forms, previewing the data to check for recording errors and to 
highlight areas of concern, and ranking problems based on the data analysis. Once the data is 
analyzed, the results should be reported, but not presented in a way that may be perceived as 
punitive or that portrays the mock tracer as an inspection. All identifying information should be 
removed. TJC suggests several ways to report results, including formal reports, conference calls 
to share results, or posting feedback on an internal organization site or room and asking for 
feedback. Also important is presenting information in a timely manner, specifically, within one 
TRACER METHODOLOGY   17 
 
month after completion and highlighting positive outcomes in order to encourage future positive 
interactions with mock tracers. 
The methods used to analyze data can remain the discretion of the organization. 
Bookbinder et al. (2015) utilized factor analysis, canonical correlation, and group comparisons to 
determine if correlations could be made between instrument items and latent variables. 
Ultimately, the data was analyzed to determine if a clinician tracer guided by a small number of 
items could effectively be used as an audit tool. The items used on the field test were chosen 
based on the results of the preliminary analysis of the pilot and survey proper. Wisdom et al. 
(2012) do not discuss the process used to analyze data, but the authors share the field tests helped 
to identify strengths and weaknesses of the instrument as a licensing tool. Additionally, the field 
tests helped to establish the feasibility of using tracer methodology, identify the strength of the 
scoring protocol, and enable the staff to work together to ensure the survey was conducted 
consistently. Likewise, Ross et al. (2017) do not discuss the use of statistical analysis to analyze 
results, but workflow processes were identified, and workflow analyses revealed the roles 
performed by staff nurses, which was then used to guide clinic policy. 
Applying results. The final step of conducting a mock tracer is to develop and 
implement improvement plans. Suggested approaches to implementing plans include handing off 
corrective actions to relevant managers, working with the organization’s performance 
improvement program, sharing plans with the entire organization, monitoring plans as they are 
implemented by appropriate departments, and preparing for future mock tracers (TJC, 2011). 
The tracer conducted by Ross et al. (2017) revealed the absence of standardized 
procedures in the clinic for pain reassessment. Therefore, the project improvement team 
recommended workflow be reviewed and modified and recommendations for improvement were 
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provided. The authors also acknowledge the importance of including primary care staff, EMR 
trainers, and clinical workflow analysts in the review and evaluation of possible solutions. 
Bookbinder et al. (2018) created a tracer tool based on staff feedback and the results of the field 
test. The authors concluded that findings revealed using the tracer tool would not be definitive, 
but instead would suggest the need for more detailed evaluation, practice change, or staff 
training. Similarly, Wisdom et al. (2012) concluded tracer methodology provided a more 
accurate assessment and follow-up of clinical issues compared to the process that emphasized 
policies and procedures, meeting minutes, and adherence to medical record documentation. Staff 
also revealed the process was more collaborative, affirming, and clinically relevant and ended 
with more agreement and clarity on clinic functioning. Overall, the implementation of 
interventions utilizing tracer methodology result in positive and valuable outcomes, however, the 
application of tracer methodology is not without challenges. 
Summary of evidence. Several studies note the importance of cooperation from staff and 
leadership. Wisdom et al. (2012) found mental health service providers were reluctant to share 
information about service users and other providers. Ross et al. attribute success to having 
leadership support and recognize conducting a stakeholder analysis helped to identify and engage 
appropriate staff members. Bookbinder et al. (2018) also acknowledge the cooperation and 
capabilities of the professionals in their study may not be applicable to other settings. 
Furthermore, the authors recognize that some tests conducted by staff in their own unit may be 
subject to bias, indicating the need for future studies to assess for rater bias. With regards to the 
sustainability of implementing tracer methodology for program evaluation, Wisdom et al. (2012) 
note the challenges in continuously incorporating feedback from clients and providers and 
ensuring consistency among the survey team. Likewise, Bookbinder et al. (2015) recognize that 
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the tracer tool utilized in their study requires validation in new samples, and the tracer should be 
tested and retested to evaluate the reliability and sensitivity to change. The authors comment that 
the results of the tracer are not definitive, but indicate a need for further assessment, change, or 
education. 
Overall, the reviewed studies suggest tracer methodology can be used not only to audit an 
organization’s policies and procedures, but as a means to evaluate system programs and staff 
performance. Information gathered from a tracer can aid organizations in creating new programs 
or improving existing programs by helping to identify deviations or deficits. Furthermore, by 
measuring more than process outcome measures, tracers also have to potential to provide reasons 
for certain patterns or deviations. Ensuring multidisciplinary input when creating a tracer appears 
paramount, as does ensuring surveyors are not prone to biases when conducting the survey. 
Additionally, allowing adequate time for surveyors to become comfortable in their role is 
important as the success of the survey relies strongly on the abilities of the surveyor. None of the 
studies reviewed discussed evaluating the consistency of tracers conducted by multiple 
surveyors, however, given the reliance of tracers on surveyors, if more than one surveyor is 
assigned, consideration should be given to inter-rater reliability.     
Conceptual Framework 
The integrated promoting action on research implementation in health services (i-
PARIHS) is the framework that guided the implementation of the tracer in the acute care setting 
(Kitson & Harvey, 2016). Kitson and Harvey (2016) examine knowledge translation (KT), also 
known as evidence-based practice. KT is the process of developing knowledge into practical 
applications for clinical practice and patient care. The authors note that historical models of KT 
are based on linear models of translation with the assumption that knowledge producers and 
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knowledge users are two separate entities. However, Kitson and Harvey (2016) cite evidence that 
multifaceted or complex interventions are more effective than simple interventions and suggest 
the use of the i-PARIHS framework to introduce KT principles into practice. Furthermore, the 
authors cite evidence that facilitation is a key component of KT, and is effective in primary care, 
community development, and acute and sub-acute care settings.  
According to the original PARIHS framework, successful implementation of evidence-
based practices relies on the quality and type of evidence, the characteristics of the setting or 
context, and the methods used to introduce or facilitate the uptake of the evidence. The core 
constructs of the i-PARIHS framework are facilitation, innovation, recipients, and context. 
Facilitation, the process of supporting individuals, groups, or teams to collectively work to 
achieve a common goal, is highlighted as being the active component in assessing, aligning, and 
integrating the other constructs (Kitson & Harvey, 2016; Schwarz, 2002). In order to effectively 
utilize a tracer as a means to evaluate a hospital ASP, facilitators were important to encourage 
the integration of tracer methodology (innovation) into the assessment practices of the hospital 
and ASP team in the acute care hospital (recipients and context) . A Doctor of Nursing Practice 
(DNP) student was designated as the novice facilitator, an administrative nursing director and a 
regional clinical coordinator pharmacist served as the experienced facilitators, and the medical 
director of pharmacy and infection control served as the expert facilitator.  
Specific Aims 
The goal of the project was to utilize tracer methodology to assess the effectiveness of a 
San Francisco Bay Area community hospital’s antimicrobial stewardship interventions through 
the evaluation of healthcare providers’ awareness of antimicrobial stewardship within their 
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institution, knowledge regarding antimicrobial stewardship components, and approach to 
prescribing antibiotics and ordering diagnostics for patients with CAP by August 2020.  
Methods 
Context 
Implementing an antimicrobial stewardship tracer in a hospital setting required 
participation and cooperation from several key stakeholders. The Medical Director of Pharmacy 
and Infection Control was aware of the need to explore tracer methodology to evaluate the ASP, 
and buy-in from the ASP team members and hospital leaders, including the antimicrobial 
stewardship pharmacist lead, the hospitalist lead, the pharmacy director, a nursing administrative 
director, and nurse managers, were necessary in order to convey the importance of the tracer to 
other staff members and leaders within the hospital. Additional key stakeholders included the 
internal medicine physicians, clinical pharmacists, and nurses, all of whom were interviewed 
during the tracer process. 
Care of patients in the hospital is multifaceted and involves input from numerous 
individuals, disciplines, and specialties. Capturing information from one component of patient 
care is challenging as the care team and treatment team is constantly changing and evolving. 
Understanding the process in which patients are assessed and admitted to the hospital was 
important in order to create a tracer that would best capture stewardship practices and potentially 
elicit obstacles or outside influences of different actions, attitudes, or behaviors. 
Intervention 
 The purpose of the intervention was to implement tracer methodology to assess the 
hospital ASP. Tracer methodology follows patients through the health care delivery system 
collecting information related to treatment or services to evaluate care provided. Tracer surveys 
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enable assessors to identify potential issues regarding performance issues within processes, or 
with interfaces between processes (TJC, 2018).  
Gap analysis. The current and past ASP evaluation methods of the hospital included 
audit and feedback, rates of usage of specific antibiotics, and prescribing rates of individual 
prescribers. In planning, developing, and conducting a tracer, then analyzing and sharing the 
data, the objective of the intervention was to create a tool to determine current antimicrobial 
prescribing practices when treating CAP, identify barriers to stewardship, and evaluate the 
knowledge of healthcare providers regarding antimicrobial stewardship (see Gap Analysis, 
Appendix C).  
The tracer in and of itself helped to identify gaps within the hospital ASP. At the 
individual patient level, the tracer assessed patient care regarding diagnostic criteria, ordered 
tests, and prescribed antibiotics. At the system level the tracer assessed if the hospital ASP has 
been effective in distributing education regarding antimicrobial stewardship and is a 
distinguishing resource for clinicians. The results of the interview portion of the tracer were 
compared to the information collected from the patient chart to determine if an association exists 
between antimicrobial prescribing practices and confidence regarding antimicrobial stewardship. 
Gaps in patient care were identified based on information collected during the tracer. 
Work breakdown structure and Gantt chart. Implementation of the tracer involved 
four components: planning, conducting, analyzing, and sharing (see Work Breakdown Structure, 
Appendix D). The process of creating and implementing the tracer for antibiotic stewardship 
began with creating a multidisciplinary team with representatives from infectious disease, 
pharmacy, and nursing. In the planning phase, the team met multiple times to determine the 
scope of the tracer and establish a schedule for creating and conducting the tracer. (see Gantt 
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Chart, Appendix E). It was important to designate who would be performing the survey in order 
to begin preparing the surveyor by establishing access to the EMR, providing education about 
ASP guidelines and standards, and offering methods for conducting the tracer.  
The DNP student assumed the role of surveyor, and while the tracer was being 
developed, the process of introducing the surveyor to clinical staff began. An introductory letter 
was sent from the experienced and expert facilitators to clinical staff to introduce the surveyor 
and the project. Additionally, the surveyor attended patient rounds for several weeks leading up 
to the tracer to meet as many hospitalists, clinical pharmacists, and nurses in person as possible, 
and, as time permitted, was introduced to nursing managers and clinical pharmacy directors and 
staff by the experienced and expert facilitators. The surveyor was also granted access to the 
electronic medical record and provided with contact information for prescribers and clinical 
pharmacists, all of which was facilitated by one of the experienced facilitators. 
To choose components that would be best reflect the overall impact of the ASP through 
meeting compliance standards, it was necessary for all team members to review the CDC’s Core 
Elements of Hospital Antibiotic Stewardship Programs: 2019 (CDC, 2019c), TJC’s New 
Antimicrobial Stewardship Standards (TJC, 2016), and the American Thoracic Society’s (ATS) 
guidelines for diagnosing and treating adults with CAP (Metlay et al., 2019). The 
multidisciplinary team met multiple times to determine the overall goals of conducting the tracer, 
including which questions and metrics would provide the most useful feedback for the 
stewardship program. It was important to ensure that tracer questions reflected components of 
the Core Elements. After deciding the tracer would focus on patients being treated for CAP, the 
team worked to integrate components of the ATS guidelines into the tracer. Additionally, the 
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team created interview questions for healthcare practitioners, with the goal of obtaining current 
practices and self-perceived knowledge. 
Once the tracer was created by the Medical Director of Pharmacy and Infection Control, 
the Clinical Coordinator Pharmacist, and the DNP student who comprised the multidisciplinary 
team tasked with creating the tracer (see Appendix F), the surveyor (also the DNP student) 
conducted several chart reviews with the tracer to identify any preliminary issues with questions 
or the tracer format. The surveyor then presented the findings to the rest of the multidisciplinary 
team and modifications were made as necessary. Once the tracer was finalized, the surveyor 
began conducting the tracer with staff interviews.  
Patient charts were selected to be surveyed if the patient had an admitting diagnosis of 
CAP; pneumonia due to infectious organism; or multifocal pneumonia. When a chart was 
identified, it was reviewed by the surveyor and used to answer questions in the ‘Infection 
Specific Questions’ and ‘All Pneumonia’ sections of the tracer which identified various 
components of care, including diagnostic criteria, laboratory and radiology testing, and ordered 
antibiotics. The admitting physician was notified and attempts were made to contact him/her for 
the interview portion of the tracer which included questions related to their knowledge of 
antimicrobial stewardship and the hospital ASP, and specifically the clinical approach to the 
patient. If more than five days had passed from the time the patient was admitted, the physician 
was not contacted. Additionally, an attempt was made to interview a nurse taking care of the 
patient on the day the tracer was conducted, as well as the clinical pharmacist responsible for 
reviewing the patient’s medications for the day, to ask questions related to their general 
knowledge of antimicrobial stewardship, the hospital ASP, and the care of the selected patient. 
Patient charts were excluded if pneumonia was suspected but antibiotics were not ordered; the 
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patient was diagnosed with COVID-19; the patient met the criteria for healthcare associated 
pneumonia; the patient was originally admitted to the intensive care unit; the patient was 
ventilated or had a tracheostomy. 
The first tracers conducted in February 2020 were conducted in-person whenever 
possible. The surveyor conducted tracers twice a week until the onset of the COVID-19 
pandemic, at which point, tracers were halted. Tracers resumed in May 2020 but were conducted 
remotely, with the interview portion of the tracer conducted via telephone. The tracers were 
conducted twice a week, however, conducting the interview portion by phone allowed more 
flexibility as to the days the surveyor could attempt to contact providers. As the tracers 
progressed, the surveyor met with at least one member of the multidisciplinary team every two to 
four weeks to review challenges encountered with implementing the tracer and discuss any 
issues or observations made regarding the tracer tool or methodology.  
 It was important for the surveyor to remain flexible while conducting the survey to meet 
the needs of the patient care team. The ability to conduct face to face interviews was helpful in 
establishing a connection with the staff member being interviewed, however, it had the potential 
to limit the available timeframes the surveyor could reach staff. In fact, even when in-person 
interviews were conducted, there were still times the surveyor conducted an interview via phone 
due to the availability and preference of staff. After the onset of the COVID-19 pandemic, all 
tracers were conducted remotely. The ability to conduct tracers remotely potentially provided the 
surveyor with more flexibility with regards to days and time spent dedicated to conducting the 
tracer and interviews. Unfortunately, conducting the tracer remotely may have contributed to 
staff being unfamiliar with the mock tracer and, therefore, more apprehensive to share 
information.   
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Once tracers were completed, the last step of the implementation was consolidating the 
data and organizing it in a meaningful way for provision to the multidisciplinary team. Results 
and lessons learned throughout the process were also presented to the systems regional 
Antimicrobial Stewardship Team. Additionally, a toolkit (Appendix G) was created to guide 
hospitals in the plan, design, and implementation of future ASP tracers. 
Responsibility/communication plan. The i-PARIHS framework guided the 
implementation of the tracer, and as such, guided communication and assignment of tasks 
amongst facilitators and from facilitators to recipients. According to the constructs of the i-
PARIHS framework, the novice facilitator was selected to lead the project with support from the 
experienced and expert facilitators (Kitson & Harvey, 2016) (See Responsibility/Communication 
Plan, Appendix H). The novice facilitator worked to apply evidence in healthcare to innovations 
in practice. In order to successfully link evidence to innovation, the novice facilitator learned 
how to assess the quality of evidence and engage colleagues in discussion about current practices 
and areas for improvement (Kitson & Harvey, 2016). The DNP student served as the novice 
facilitator and conducted a review of tracer methodology, including past applications, and 
reviewed antimicrobial stewardship guidelines to establish an understanding of ASP 
requirements from TJC and CMS and present the findings to the established multidisciplinary 
tracer team.  
The DNP student worked to understand the organizational structure of the hospital, with a 
specific focus on learning organizational priorities in order to garner support from hospital 
leadership and senior management. As the novice facilitator, the DNP student was supported by 
an administrative nursing director and regional clinical coordinator pharmacist serving as 
experienced facilitators. The nursing administrative director helped to orient the novice 
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facilitator to the hospital by familiarizing the novice to the setting, introducing the novice to 
appropriate leaders and managers, facilitating access to the electronic medical record, and 
facilitating remote access as necessary. Additionally, as an internal member of the organization, 
the nursing director was able to positively promote the innovation to stakeholders.  
The regional clinical coordinator pharmacist provided guidance by helping the DNP 
student understand different ASP interventions and processes related to antimicrobial prescribing 
in the hospital.  Understanding how to implement new evidence into routine practices enabled 
the experienced facilitators to support the novice facilitator with issues related to recipients and 
context. The medical director of pharmacy and infection control fulfilled the role of the expert 
facilitator by supervising the project and providing guidance to the DNP student. An expert 
facilitator is able to work across academic, service, and other organizational boundaries to 
actively incorporate evidence-based practices (Kitson and Harvey, 2016). In the implementation 
of the tracer, the expert facilitator aided in troubleshooting various strategies and provided 
insight into the potential strengths and weaknesses of implementing such methodology. 
SWOT analysis. In conducting a SWOT analysis (see Appendix I for SWOT chart), 
potential strengths of utilizing tracer methodology for ASP evaluation included: (a) the ability to 
assess the knowledge of individual prescribers, pharmacists, and nurses regarding antibiotic 
prescribing, (b) the ability to establish resources available to clinicians, and (c) the potential to 
elicit the rationale regarding prescribing habits. Furthermore, tracer methodology enabled the 
assessor to gather information directly from the EMR to evaluate the impact of system wide 
interventions of education, antibiotic formularies, patient rounding, and diagnostic testing. While 
interviews and chart reviews can be conducted on site, the nature of the tracer allowed for 
information to be collected by phone or remotely, which helped to ensure efficiency for both 
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staff and the assessor. The development of the tracer by a multidisciplinary team provided the 
unique perspective of each profession. Additionally, the tracer focused on care provided for one 
specific infection, allowing for a more focused assessment, and the chosen infection of 
pneumonia has established treatment guidelines. Lastly, completion of the tracer by an outside 
assessor provided the potential of less risk of bias. 
 Potential weaknesses included the time involved to conduct the tracer, as well as 
coordinating prescriber and pharmacist schedules with the day the tracer was conducted. For the 
purposes of this tracer, the practices of the admitting physician were evaluated, however, 
questions pertaining to specimen collection and antibiotic timing and review required the patient 
to receive care for more than the initial first day. The admitting hospitalist may not have been 
available on day three of the patient’s hospital stay. Additionally, the clinical pharmacist 
responsible for reviewing antibiotics on day three may not have been available every day. The 
perception of prescribers, pharmacists, and nurses, and their willingness to cooperate and 
participate also influenced the success of the tracer. The assessor had additional challenge of 
earning buy-in from stakeholders who were unfamiliar with them. Also, the accuracy of the 
tracer is dependent on the surveyor’s knowledge of the charting system and ability to find 
information. Moreover, the tracer does not account for legitimate deviations from standard 
antibiotic therapy. 
 Potential opportunities include the fact that tracer methodology is evidence-based and 
utilized by accrediting agencies to evaluate various aspects of patient care and system processes. 
In the instance of ASPs, a state government agency responsible for promoting hospital ASPs has 
proposed the utilization of tracer methodology to evaluate the effectiveness of hospital ASPs as 
TJC and the DNV-GL now use the Core Elements as a basis for accreditation standards. 
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Additionally, the questions posed to staff have the potential to become an indirect way of 
providing antibiotic stewardship education and impress the importance of ASPs within the 
hospital.  
Potential threats to implementing tracer methodology for the evaluation of ASPs within 
hospitals include the financial investment to implement and sustain the program and the amount 
of time involved to conduct the tracer. While the review of the electronic health record and 
interview can be streamlined, infections such as pneumonia are multifaceted, therefore, the 
approach to treating pneumonia can vary based on the patient. Such variation has the potential to 
confound data if questions lack direction or the surveyor is inexperienced or unfamiliar with the 
process. The tracer as a source of information is only as valuable as the surveyor is conscientious 
in data collection. 
Budget and break-even analysis. The proposed budget considered the number of hours 
required by the employees with the largest contributions of time when developing and 
implementing the tracer. Hours for the medical director of pharmacy and infection control and 
the regional clinical coordinator pharmacist were related to the creation of the tracer and 
provision of guidance and feedback as needed. The DNP hours were accrued based on time spent 
creating and implementing the tracer.  
The incremental cost to treat an antibiotic resistant infection is: $1,383 per patient 
(Thorpe, Joski, & Johnston 2018). Therefore, if the total cost to develop and implement the 
tracer is $16067, to break even, antimicrobial resistant infections need to be prevented in 12 
people (see Appendix J for Budget and Break-Even Analysis). 
Study of the interventions. Data was collected using the proposed tracer (see Appendix 
F). The face validity of the tracer was determined during the creation of the tracer. The first draft 
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of the tracer was distributed to all members of the survey team to review. The tracer was revised 
according to comments and suggestions received, then distributed to members again for final 
approval. Content validity was assessed once the survey was complete and data was analyzed 
and discussed. During the course of the survey, the surveyor determined that certain questions 
were not effective as the intervention was difficult to assess from a review of the chart, or the 
question implied the intervention was being implemented and practiced, when, in fact, it was not. 
Additionally, the surveyor noted questions found to be non-specific, therefore making the 
answers more susceptible to being misinterpreted. 
Measures 
The main goals of the tracer (see Appendix F) were to evaluate antimicrobial stewardship 
awareness and knowledge of physicians, clinical pharmacists, and nurses working at the hospital. 
The outcome measures were related to questions assessing clinician knowledge and awareness 
during the interview portion, and treatment approaches collected during the EMR tracer. 
Outcome measures included: Physician knowledge of hospital ASP; nurse knowledge of hospital 
ASP; clinical pharmacist knowledge of hospital ASP; physician self-reported confidence 
regarding pneumonia treatment; and compliance with ATS treatment guidelines for CAP.  
Specifically, the tracer was expected to capture the percentage of interviewed providers 
aware of the ASP and using appropriate antimicrobial prescribing protocols. Data collected 
through interviews was compared to data collected from the EMR, with the intent of identifying 
strengths or weaknesses in antimicrobial stewardship practices as they related to the self-reported 
knowledge and confidence surrounding stewardship by the healthcare providers. Qualitatively, 
observations made by the surveyor regarding the attitudes of providers toward being interviewed 
and toward specific questions were also noted. 
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Analysis 
The surveyor deidentified information from the charts and interviews and filed the forms 
electronically as the tracers were being completed. Once all the tracers were completed, the 
surveyor reviewed the data to ensure all information was recorded and coded correctly. The 
yes/no questions and answers were tabulated using an Excel spreadsheet. The answers to the 
questions which allowed open answers were coded according to identified categories and 
themes.  
To analyze the collected information, answers were organized into tables and charts from 
Excel, and then data from the interview portion of the tracer was compared to the data collected 
from the patient chart. The intention of comparing data from the two parts of the tracer was to 
determine if an association existed between antimicrobial prescribing practices, confidence 
regarding antimicrobial stewardship, and self-reported knowledge regarding antimicrobial 
stewardship. 
The small number of patient charts reviewed, and smaller number of clinicians 
interviewed, created a limitation when interpreting the results. However, as there are a set 
number of staff within the hospital, and repeat interviews within the same tracer cycle are not 
desirable, an increased number of chart reviews would perhaps only aid in a better understanding 
of the processes taking place. Data collected on the proposed outcome measures could still be 
analyzed, but attention was shifted to also include knowledge garnered through observations 
regarding methodologies applied during the tracer. Such observations can help to guide future 
tracers and provide insight into the stewardship knowledge and practices of healthcare providers 
within the hospital.  
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Ethical Considerations 
This project was evaluated and approved as a quality improvement project through the 
University of San Francisco School of Nursing and Health Professionals (see Appendix K for 
Statement of Non-Research Determination). The project was undertaken as an evidence-based 
change of practice project and as such, did not need to be supervised by the Institutional Review 
Board. Priority was given to confidentiality and privacy by blinding data retrieved from the 
EMR. Ensuring patient privacy during chart audits was essential, as was maintaining 
confidentiality of prescribers, clinical pharmacists, and nurses during interviews. To protect the 
identity of patients and healthcare personnel, a coding system was implemented to de-identify 
the hospital, interviewee, and patient. 
Collecting information and data regarding antimicrobial prescribing practices and barriers 
to antimicrobial stewardship was done with the ultimate goal of improving patient care and 
preserving antimicrobials for future use. The purpose of this project was in accordance with the 
Jesuit values and the American Nurses Association (ANA) Code of Ethics. The implementation 
and outcomes served to fulfill a social responsibility of creating, communicating, and applying 
knowledge that will assist with responsible utilization of healthcare resources (University of San 
Francisco, n.d.). Furthermore, according to Provision 6 of the ANA Code of Ethics, in order to 
encourage safe, quality healthcare, the nurse is expected to establish, maintain, and improve the 
ethical environment of the work setting (American Nurses Association, 2015). Implementing 
tracer methodology to evaluate a hospital ASP seeks to create a new assessment method to 
improve and encourage antimicrobial stewardship which supports nurses and other health 
professionals in the fulfillment of their ethical obligations. 
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Results 
In total 15 tracers were completed from February 2020 to July 2020, with a pause in 
conducting tracers from the beginning of March to the end of May due to COVID-19. Within the 
15 tracers, seven physician interviews, nine nurse interviews, and five clinical pharmacist 
interviews were conducted. The focus of the tracer was on the admitting physician, nurse caring 
for the patient on the day of the tracer, and the clinical pharmacist caring for the patient on the 
day of the tracer. The data being collected, however, was often generated over several days and 
in the days preceding the tracer. 
Tracer Results 
All raw data was provided to the hospital medical director of pharmacy and infection 
control and the regional clinical coordinator pharmacist, however, as the onus of antimicrobial 
stewardship in the hospital falls to physicians, results from the physician interviews and EMR 
review were highlighted in the presentation to the regional System Antimicrobial Stewardship 
committee (see Appendix L and Appendix M). Specifically, with regard to general knowledge of 
the hospital ASP, it was noted that of the seven physicians interviewed, six stated they were 
aware of the hospital ASP prior to being interviewed, five recognized the hospital had specific 
guidelines for common infections, and all seven stated the hospital implemented specific 
antimicrobial stewardship interventions. However, when asked to specify interventions, answers 
varied widely. Answers included the following responses: (a) someone calling to review 
prescribing, (b) receiving a prescribing report with the overall percentage of antibiotics 
prescribed for select antibiotics, (c) patient rounding, (d) antibiotic specific education, (e) order 
sets, and (f) receiving input from the pharmacy. Only education, patient rounding, and 
prescribing reports were cited by more than one physician. With regards to self-reported 
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knowledge, all physicians interviewed stated they had adequate knowledge of the treatment of 
pneumonia to choose empiric antibiotic therapy. Of the EMRs reviewed, all patients were 
appropriately prescribed standard empiric therapy.  
Factors influencing treatment revealed some inconsistencies with chart documentation 
and following guidelines. Physicians reported the following multiple resources used to determine 
a definitive antimicrobial regimen: (a) clinical guidelines, (b) clinical condition of patient, (c) 
procalcitonin level, (d) minimum therapy of three days for treatment, (e) culture and sensitivity 
results, (f) infectious disease consult, (g) UptoDate, (h) type of infection, and (i) clinical 
improvement of the patient. Only clinical guidelines, clinical condition, and infectious disease 
consult were cited by more that one physician.  
The EMR review sought to detect diagnostic criteria identified by the ATS/IDSA clinical 
practice guidelines for the treatment of CAP. Of the 15 patient charts reviewed five patients were 
tested for influenza, nine patients were not tested, and one patient chart was missed. The 
guidelines state patients should be tested when influenza was circulating in the community 
(Metlay et al., 2019). It was noted that this result is somewhat difficult to interpret as the tracer 
was halted from March to June, but it may have been easier to interpret if results were collected 
from charts in winter and early spring when influenza is more prominent. Other diagnostics 
reviewed included urine tests for Legionella and pneumococcal antigens. The recommendation is 
to not routinely check for these antigens except in patients with severe CAP (Metlay et al., 
2019). Only three of the patient charts reviewed met IDSA/ATS criteria for severe CAP, yet 
seven patients were tested for the Legionella antigen and four were tested for the pneumococcal 
antigen. The discrepancy in Legionella and pneumococcal antigen testing is interesting, as is the 
divergence in the number of patients tested for Legionella and pneumococcal antigens compared 
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to the number of patients meeting the diagnostic criteria for severe pneumonia. Lastly, 
procalcitonin is not recommended to determine need for initial antibiotic therapy, but it is 
acknowledged it may be helpful to monitor (Metlay et al., 2019). Of the patient charts reviewed, 
nine patients had a serum procalcitonin level ordered prior to the initiation of antibiotics or prior 
to the second dose of antibiotics, but six did not. 
Of the questions related to factors influencing treatment of MRSA, P. aeruginosa, and 
other MDROs, physicians cited multiple criteria to determine risk for such organisms. The intent 
of the questions regarding MDROs was to evaluate knowledge regarding risk factors and 
treatment. The answers were found to be varied and inconsistent. Criteria cited included: (a) 
prior isolation of P. aeruginosa, (b) prior isolation of MRSA, (c) recent hospitalization and 
exposure to parenteral antibiotics, (d) arrival from facility with known MDROs, and (e) an 
‘other’ category. The EMR review revealed vancomycin was ordered for three of the 15 patients, 
however, a MRSA PCR was only ordered for one of the three patients. A pretreatment gram stain 
and culture of lower respiratory secretions was ordered for three patients, but the three patients 
for which the gram stain were ordered differed from the patients for whom vancomycin was 
ordered and the patients did not meet the criteria for severe-CAP according to the 
documentation. The guidelines recommend obtaining a pretreatment gram stain and culture of 
respiratory secretions in adults being treated for CAP in the hospital who are classified as severe 
CAP, or are being empirically treated for MRSA or P. aeruginosa, or who were previously 
infected with MRSA or P. aeruginosa, or who were hospitalized and received parenteral 
antibiotics in the last 90 days (Metlay et al., 2019).  
Data presentations. The final step of the tracer was presenting the results of the tracer 
and lessons learned about applying the methodology to ASP assessment to the hospital medical 
TRACER METHODOLOGY   36 
 
director of pharmacy and infection control and the regional clinical coordinator pharmacist (see 
Appendix L). Additionally, some results and the lessons learned regarding methodology were 
presented to the regional System Antimicrobial Stewardship committee of which the medical 
director of pharmacy and infection control and the regional clinical coordinator pharmacist are 
members. Results were communicated in a written report which presented data collected for each 
question on the tracer. Qualitative data was provided from interview questions, and annotations 
were added to questions found to need clarification or revision. A PowerPoint presentation was 
also created for the regional System Antimicrobial Stewardship committee and presented 
virtually during a regularly scheduled meeting (see Appendix M).  
Tracer observations/recommendations. Collecting data retrospectively provided 
insight into the approach to caring for patients with a diagnosis of CAP and highlighted that 
caring for such patients is a team approach. The surveyor observed that often when the admitting 
physician admits the patient, the initial orders do not necessarily include all recommended 
diagnostic tests, but the tests may eventually be ordered by consulted specialists or hospitalists 
on subsequent days. Thus, with regards to lessons learned in applying tracer methodology for 
ASP evaluation, it was concluded future tracers must carefully consider the presentation of 
questions and designate medications, tests, and processes by specialty or department to help 
establish progression of treatment and propensity of providers.  
 With regards to staff participation, including attitudes toward the tracer, it was noted that 
willingness to participate and enthusiasm varied by discipline. Regardless of discipline, 
willingness to participate was greatly influenced by current workload. Amongst physicians, 
attitudes toward participation also seemed to be influenced by past experiences with feedback 
related to their antimicrobial prescribing practices.  
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Incidentally, the surveyor also found some uncertainty existed regarding the classification 
of the severity of patients’ pneumonia complicating some aspects of the tracer. Aside from 
reviewing the chart for criteria from a validated definition, there is no standardized designation 
in the patient chart to distinguish CAP from Severe-CAP. The clinical practice guidelines 
approved by the American Thoracic Society (ATS) and Infectious Disease Society of American 
(IDSA) in 2019 provide criteria for defining severe-CAP and use the distinction to indicate 
which diagnostics are recommended. Future tracers should further evaluate the sensitivity and 
specificity of the criteria as it pertains to patients admitted to the hospital for CAP. No physicians 
cited the ATS and IDSA guidelines and several physicians listed criteria not included when 
determining the course of treatment for patients. 
The results of the tracer can be used as an educational opportunity for participants, 
though, ultimately, the ASP team is responsible for reviewing the results and planning future 
interventions. Additionally, as knowledge and insight evolved regarding the creation and 
implementation of an ASP tracer, a toolkit was developed to guide future efforts. The 
implementation toolkit (see Appendix G) includes guidance regarding selection of team 
members, recommendations for strategies to create the tracer tool, and offers considerations to be 
made when deciding metrics to be investigated. 
Discussion 
Summary 
Antimicrobial stewardship will remain an important part of providing safe, quality 
healthcare, therefore, healthcare facilities must find ways to efficiently and effectively evaluate 
programs. Utilizing a method that evaluates process measures while simultaneously assessing 
barriers to appropriate antibiotic prescribing has the potential to provide valuable feedback and 
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empower involved stakeholders to meaningfully contribute to quality improvement projects 
within their institutions. The completed tracers provided insight into the effectiveness of the ASP 
program and helped to identify trends with regards to resources used, efficacy of currently 
utilized feedback methods, and potential knowledge gaps. The ability of a tracer to provide 
valuable information relies heavily on the quality of questions and the ability of the surveyor to 
understand and identify questions that may provide imprecise answers. Often, survey questions 
aspire to have definitive answers, however, answers may not always be interpreted definitively in 
the context of the multifaceted nature of patient care in an inpatient setting, under the 
circumstances of an evolving infection, and during transfer of care between providers and 
departments. 
 Future application of tracer methodology to evaluate antimicrobial stewardship must be 
sensitive to the multiple providers and departments involved in caring for patients receiving 
antimicrobials. Future tracers should remain sensitive to the time required of staff to participate 
in the tracer, including considering the use of e-surveys to obtain information for follow-up 
(North et al., 2009). Some information may best be collected in the form of a survey or 
interview, but the value of requesting staff to demonstrate the location of items in the chart, for 
example, an order set, versus questioning knowledge of an item should not be underestimated. 
Such a technique allows more accurate assessment and potentially decreases the provider’s 
perception that their judgement or knowledge is being tested. 
If a tracer can successfully be created and implemented to evaluate a hospital ASP, then 
applying the method to evaluate ASPs in outpatient and long-term care facilities should also be 
considered, as antimicrobial stewardship recommendations exist for these institutions which are 
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also subject to review from TJC and CMS (CDC, 2015; CMS, 2016; Sanchez et al., 2016; TJC, 
2019). 
Interpretation 
As was demonstrated in other projects in which a tracer was developed and implemented, 
the establishment of a multidisciplinary team was an important component in the development of 
the ASP tracer (Bookbinder et al., 2015; Padgette & Wood, 2018; Ross et al., 2017; Wood et al., 
2012). Just as Wisdom et al. (2012) noted providers were reluctant to share information about 
service users and other providers, the ASP tracer found that providers were not only sometimes 
reluctant to answer questions, but also suspicious as to why the information was being collected. 
While leadership provided support for the project and facilitated its implementation, increasing 
the visibility of the project in future tracers and involving more stakeholders may lessen such 
reluctance. Moreover, the importance of choosing appropriate methods to introduce the project 
and the role of facilitation in implementing a new practice in the hospital was evident in the 
reluctance displayed by many staff members. Understandably, many resources were directed 
toward the COVID-19 pandemic, but future tracers must be prioritized by experienced and 
expert facilitators to integrate tracer methodology as an assessment method within the hospital 
(Kitson & Harvey, 2016).   
Assigning a surveyor from outside the hospital potentially limited bias but may also have 
contributed to reluctance to participate. In fact, future endeavors may wish to involve hospital 
clinical pharmacists more, as stewardship pharmacists are likely key in ensuring trust amongst 
other providers with respect to the tracer. With regards to specifically implementing the tracer, 
Bookbinder et al. (2015) highlighted the importance of training the surveyor in tracer 
methodology and obtaining information from front-line clinicians. Indeed, the ability of the 
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surveyor to effectively obtain information from staff during the ASP tracer hinged on knowledge 
of tracer methodology, familiarity with the tracer questions, and the ability to make observations, 
while collecting data. If data is collected by hospital staff, assessing for rater bias will be 
necessary (Bookbinder et al., 2018). Furthermore, if a tracer is conducted by more than one 
surveyor, testing inter-rater reliability will also be important.  
Padgette and Wood (2018) noted it is important to ensure the number and type of patients 
observed allow for adequate validation of the practices and processes being evaluated. While the 
sample size in the ASP tracer was small, focusing on patients with CAP provided a more focused 
outcome, which was helpful when reviewing a process as multifaceted as antimicrobial 
prescribing and stewardship. Unfortunately, the small sample size also makes the results less 
generalizable.  
Ross et al. (2017) identified workflow processes and roles of staff with a tracer and 
applied the knowledge to guide clinic policy, the observations and lessons learned in the ASP 
tracer with regards to staff receptiveness, intention of questions, and focus of questions can be 
applied to future assessments and education topics. Just as Wisdom et al. (2012) concluded that 
tracer methodology provided a more accurate assessment and follow-up of clinical issues as 
opposed to processes emphasizing policies and procedures, likewise, the ASP tracer revealed the 
steps involved in prescribing antibiotics are not straightforward and are influenced by variables 
not only related to the patient, but also to the provider, the specialty, the department, or even the 
day.  
Nevertheless, the various components involved in antimicrobial stewardship that make 
utilizing tracer methodology an appealing assessment technique also contribute to the challenges 
of implementing future tracers in a sustainable manner. Wisdom et al. (2012) note the challenges 
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in continuously incorporating feedback and ensuring consistency among the survey team, and 
Bookbinder et al. (2015) observe that tracers continuously require testing and validity to evaluate 
reliability and sensitivity to change. Maintaining a tracer that is current and relevant to the 
practices within the hospital, and ensuring surveyors are consistently and uniformly educated 
requires a commitment and investment from hospital administrators. Yet, an ASP tracer has the 
potential to fulfill the required core elements of tracking, reporting, and education as the tracer is 
capable of collecting data related to antimicrobial prescribing practices and indirectly educating 
staff on antimicrobial stewardship. Moreover, results can not only be shared with staff, but can 
also be used to guide further evaluation, influence policies, and inform educational interventions 
(Bookbinder et al., 2018; Wisdom et al., 2012). 
Limitations 
The project was to be initiated early 2020 with the first tracers to be conducted in 
February which seemed advantageous when attempting to survey as many cases of CAP as 
possible based on the usual seasonal trend of increased CAP admissions in the winter and spring 
seasons (Murdoch, et al., 2014). However, arguably the biggest limitation in conducting this 
particular tracer was the occurrence of COVID-19. Surveys had to be halted at the beginning of 
March, then resumed at the end of May and continued until the middle of July, though the 
number of cases able to be captured on days the surveyor was able to conduct tracers decreased 
over time. The small number of patient charts reviewed, and smaller number of clinicians 
interviewed created a limitation when interpreting the results. 
The first tracers conducted in February were conducted in-person whenever possible. The 
ability to conduct face to face interviews was helpful in establishing a connection with the staff 
member being interviewed, however, it had the potential to limit the available timeframes the 
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surveyor could reach staff. In fact, even when in-person interviews were conducted, there were 
still times the surveyor conducted an interview via phone due to the availability and preference 
of staff. After the onset of the COVID-19 pandemic, all tracers were conducted remotely. The 
ability to conduct tracers remotely potentially provides the surveyor with more flexibility with 
regards to days and time spent dedicated to conducting the tracer and interviews. Unfortunately, 
conducting the tracer remotely may have contributed to staff being unfamiliar with the tracer 
and, therefore, more apprehensive to share information.  Furthermore, as the tracer focus is on 
the diagnosis of CAP, the outbreak of COVID-19 presents a unique challenge as it has the 
potential to cause viral pneumonia. Consideration must be given to the potential for the 
pandemic to alter the approach of healthcare providers when caring for patients with pneumonia. 
Remote access and phone interviews helped to minimize unnecessary exposure to non-essential 
individuals.  
Challenges were also encountered with regards to the willingness and ability of staff 
members to participate in the interview. Physicians often cited being too busy as a reason to not 
be able to answer questions. One physician did not have access to the electronic medical record 
at the time of the interview and could not remember the patient in question. In several instances 
the physician did not return messages requesting a return call in order to conduct the interview. 
With regards to nursing staff, a major challenge was trying to find times the nurses were able to 
answer questions. Often, nurses were called multiple times in an attempt to accommodate their 
schedules. Additionally, when tracers were resumed in May, several nurses refused to answer 
patient specific questions citing patient privacy. Staff seemed unfamiliar with the project despite 
an introductory letter being sent to units at the beginning of the project. The clinical pharmacists 
were often the easiest staff to contact for interviews. In only one instance did the clinical 
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pharmacist state she did not have time, though she did return the surveyor’s call, but the surveyor 
was unable to conduct the interview at the time. 
 In addition to challenges related to finding acceptable times to speak with staff, the 
receptiveness and openness of staff varied amongst disciplines. The success of the interview 
portion of the tracer hinged on the willingness of staff to answer candidly and honestly. Staff 
members were continually reassured their responses were anonymous, however, it was not 
uncommon for physicians to appear apprehensive, as evidence by questions such as, “Why did 
you choose me?” or “What did I do wrong?” The attitude amongst nursing staff varied with some 
nurses appearing eager or enthusiastic, as evidenced by the details shared in their answers, while 
others appeared rushed as evidenced by the need to end interviews early and answers that were 
vague. The clinical pharmacists appeared the most open and eager to participate and share their 
knowledge, observations, and thoughts.    
Unfamiliarity with the surveyor also seemed to generate a certain level of reluctance. 
Certainly, during a tracer conducted for accreditation, the surveyor is unfamiliar to staff, 
however, during a process improvement project, the importance of establishing trust was 
underscored. Care must also be taken to ensure questions are perceived as assessing the process 
or program and not the provider. The intent of the tracer is to evaluate the ASP program, 
therefore, staff should not be made to feel as though their knowledge or the quality of care they 
provide is being questioned. 
 The greatest potential barrier to completion of tracers is the time required to complete a 
tracer for the surveyor and those being interviewed. The tracer needed to be conducted on the 
third day of patient care as required by questions regarding review of antibiotics. This 
requirement presented a challenge with regards to scheduling. The surveyor may not be able to 
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conduct tracers on site daily and the prescriber may not be available several days later. However, 
this challenge can potentially be mitigated if the surveyor is able to access the patient chart 
remotely, thus, providing the opportunity to review the chart off site. Additionally, while not 
ideal, interviews with prescribers, nurses, and clinical pharmacists can be conducted via 
telephone. The ability to conduct phone interviews provides flexibility to both the surveyor and 
the healthcare professional being interviewed.  
While the interview portion of the tracer offers valuable insight into the general 
knowledge of antimicrobial stewardship and the ASP program at the hospital, it may be more 
efficient to obtain the information in a questionnaire or survey and save only select questions, 
particularly those that require demonstrations for the in-person interview. North et al. (2009) 
discuss the value of utilizing an e-survey to address areas identified in a tracer that require 
follow-up. The authors state that an e-survey can either assess the extent of a particular standard 
knowledge gap or provide information about a gap area. E-surveys are able to complement tracer 
methodology by expanding the range of assessment of standard knowledge, much like the 
intention of the interview portion of the tracer that was implemented (North et al., 2009). Given 
the limited time staff members have to answer questions, completing the interview portion at a 
time separate from the tracer questions may decrease the burden on staff. Additionally, the 
ability to reach staff in multiple departments may help to increase the scope of the tracer and 
increase understanding of stewardship practices within different departments of the hospital. For 
example, many, if not all, patients admitted with CAP start in the Emergency Department which 
is often where they receive their first dose of antibiotics. The surveyor noted that Emergency 
Department physicians seemed to have a preference for which empiric therapy they prescribed 
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which differed from hospitalists’ preferences, however, the tracer was not equipped to capture 
such a difference.  
Administering an anonymous e-survey may encourage staff to provide more thoughtful, 
candid answers, however encouraging participation may be difficult and the ability to correlate 
individual answers to practice would be forfeited. North et al. (2009) also note e-surveys are able 
to determine baseline knowledge and then assess and quantify improvement in knowledge over 
time. Since tracers can be used as an opportunity for education, the ASP team may find it 
interesting to assess any changes in knowledge and practice related to modifications or additions 
to the hospital ASP. 
Conclusions 
Ultimately the question remains whether tracer methodology can be implemented to 
assess a hospital ASP. Hospital ASPs are multifaceted as they must incorporate numerous 
components including staff education, interventions to improve antibiotic use, pharmacy 
expertise, and tracking and reporting (CDC, 2019d) and target multiple disciplines. However, 
much of the onus falls to the physicians or other advanced practice providers (APPs) responsible 
for assessing and determining the appropriate treatment plan for patients. A successful tracer 
demonstrates whether certain actions are occurring, but it may be difficult to apply tracer 
methodology to educe the reasons why certain actions are or are not occurring. The goal of many 
ASP interventions regarding education and feedback, is to influence the internal processes of 
providers and enhance the quality of patient care. In the instance of CAP, assessing the type of 
empiric antibiotic therapy ordered upon initial diagnosis is straightforward, however, the internal 
processes used by the practitioner, such as reasons for ordering certain diagnostics or 
determining the severity of a patient’s condition, are more difficult to capture objectively.  
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The implemented tracer provided insight into the progression of patient care upon 
admission from the ED to the hospital and revealed the complex manner in which patient care 
progresses after the initial admission.  Tracer methodology can be applied to assessing various 
components of an ASP, but it must be understood that an interpretation of the results is not 
necessarily straightforward. Tracer questions should be specific to ensure clarity in the results, 
however, specific questions may prompt providers, therefore jeopardizing organic answers. If 
used by an accrediting body to evaluate an ASP, care must be taken that results are not 
interpreted too narrowly, unless questions have been tested and found to elicit answers with no 
other explanation.  
The implementation of a tracer to evaluate a hospital ASP has the potential to provide 
constructive feedback to the ASP team regarding successful interventions, as well as identify 
potential gaps or deviations from evidence-based practices. The portion of the tracer that seeks to 
ascertain the knowledge of clinicians regarding general antibiotic stewardship and the ASP 
within the hospital will provide valuable information when compared to information collected 
from the patient chart related to antimicrobial prescribing practices. The purpose of this ASP 
tracer was not to be punitive in any way. Therefore, regardless of the results, sharing the results 
with hospital leadership and employees can provide valuable education, especially if presented 
with transparency. Requesting feedback from all stakeholders will aid in the development and 
implementation of new interventions aimed at addressing the issues uncovered.  
Once the tracer has been successfully implemented, future tracers can be conducted to 
evaluate whether the initial tracer had an impact on clinicians with regards to antimicrobial 
prescribing. However, future tracers will require updates to account for interventions 
implemented as a result of previous tracers. The same process implemented to create and 
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conduct the original tracer can be utilized. Additional research may be needed if new standards 
or guidelines are available, and new questions should be added to account for interventions 
implemented as a result of information gathered from the first tracer. Also, the potential for 
accrediting agencies to implement tracers to evaluate ASPs remains a possibility, thus, future 
tracers can also be modified to better reflect feedback received from such institutions.  
If a tracer can successfully be created and implemented to evaluate a hospital ASP, then 
applying the method to evaluate ASPs in outpatient and long-term care facilities should also be 
considered, as antimicrobial stewardship recommendations exist for these institutions which are 
also subject to review from TJC and CMS (CDC, 2015; CMS, 2016; Sanchez et al., 2016; TJC, 
2019). According to the CDC, approximately half of antibiotics prescribed in the outpatient 
setting are inappropriate (Sanchez, et al., 2016). Ross et al. (2017) and Wisdom et al. (2012) 
demonstrate that tracer methodology can successfully be applied to the outpatient setting. Thus, 
it would be reasonable to apply tracer methodology to evaluate fulfillment of the core elements 
of outpatient antibiotic stewardship and the core elements of nursing home antibiotic 
stewardship. 
The ability of tracers to help hospitals not only identify potential deficiencies, but the 
reasons contributing to deviations from evidence-based practices provides healthcare settings 
with a potentially invaluable evaluation tool. The existence of such explanatory evaluation tools 
is important when designing and creating education and interventions aimed at helping 
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*Johns Hopkins Hospital/The Johns Hopkins University (2017). Appendix F: Non-Research evidence appraisal tool. Retrieved from https://www.hopkinsmedicine.org/evidence-
based-practice/_docs/appendix_f_nonresearch_evidence_appraisal_tool.pdf
TRACER METHODOLOGY   57 
 




























nt and field 




























































care unit, or 

































for Physicians: 32 
items 








-Small number of items 
could be used to validly 
capture items 
  


















-sample size, too 
much missing data 













*Johns Hopkins Hospital/The Johns Hopkins University (2017). Appendix F: Non-Research evidence appraisal tool. Retrieved from https://www.hopkinsmedicine.org/evidence-
based-practice/_docs/appendix_f_nonresearch_evidence_appraisal_tool.pdf
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--clinic staff impacted by lack of 
standardized procedures and 
heavy reliance on staff memory 
-three distinct workflow processes 
identified: exam room, treatment 
room, examination room to 
treatment room 
-staff nurses perform one of three 
roles: triage nurse, nurse assigned 
to a provider or exam room, nurse 
assigned to the treatment room 
-nurses administering medications 
had to continually assess patients 
in multiple locations while also 
rotating patients through exam 
rooms 
-documentation could occur with 
computers in multiple rooms 
-nurse administering medication 
had several steps to complete 
-workflow did not allow or 
allowed only limited information 
exchange about patients moving 
from exam to treatment room. No 
formalized handoff procedure. 
  
*Level V, A 
 
Strengths: 
-small tracer sample 
size allowed thorough 










-only one large 
primary care clinic 
-Military’s current 
EMR may not be 
generalizable to other 
populations and 
settings 
-small tracer sample 
size limits 
generalizaof findings 
-clinic relocated in 




*Johns Hopkins Hospital/The Johns Hopkins University (2017). Appendix F: Non-Research evidence appraisal tool. Retrieved from https://www.hopkinsmedicine.org/evidence-
based-practice/_docs/appendix_f_nonresearch_evidence_appraisal_tool.pdf
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process will require 
continued updating 
  
*Johns Hopkins Hospital/The Johns Hopkins University (2017). Appendix F: Non-Research evidence appraisal tool. Retrieved from https://www.hopkinsmedicine.org/evidence-
based-practice/_docs/appendix_f_nonresearch_evidence_appraisal_tool.pdf
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Current State Desired State 
• Existing ASP 
• Evaluation of stewardship practices include: 
audit and feedback, rates of usage of 
specific antibiotics, prescribing rates of 
individual prescribers 
• Tracer to determine current antimicrobial 
prescribing practices when treating CAP and 
identify barriers to AS 
Gap Action Plan 
• Tracer to evaluate antimicrobial prescribing 
practices and barriers to AS does not exist 
Plan 
• Establish multidisciplinary team to develop 
tracer 
• Designate surveyors to conduct tracer, 
provide training/education 
• Create tracer based on CDC’s Core Elements 
of Hospital Antibiotic Stewardship Programs, 
TJC’s New Antimicrobial Stewardship 
Standards, and the American Thoracic 
Society’s guidelines for diagnosing and 
treating adults with CAP 
Conduct 
• Surveyor to begin conducting tracer 
Analyze 
• Data to be analyzed 
• Qualitative results to be compared to 
quantitative data relating to antimicrobial 
prescribing practices 
Share 
• Results to be shared with hospital 
leadership, ASP team, and survey 
participants 
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Appendix D 
Work Breakdown Structure 
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Appendix F 
Tracer Tool 
Antimicrobial Stewardship Program Tracer 
 
Purpose: Assess and/or validate organizational Antimicrobial Stewardship Program (ASP); 
identify potential gaps or deviations from evidence-based practices and internal/external 
guidelines; identify obstacles to Antimicrobial Stewardship (AMS); educate/inform physicians, 
advanced practice providers (APPs), and nurses regarding appropriate antibiotic prescribing 
practices 
Interviewee: Hospitalist, APP, attending of record for patient admitted to the hospital, nurses, 
pharmacists 
 
For Physicians and APPs: 
 
Factors influencing prescribing (Action): patient specific 
 
1) Prior to today, were you aware of your hospital having an antimicrobial stewardship 
program (ASP)? ☐ yes ☐ no ☐ unsure 
 
2) If YES to #2, do you know who the ASP leaders are at your hospital/institution?  
☐ yes ☐ no  
 
3) Do you think you have adequate knowledge on the treatment of pneumonia to choose 
empiric antibiotic therapy? 
☐ yes ☐ no 
4) What resources do you use when needed when choosing empiric antimicrobial therapy? 
(Examples could include: institution specific clinical guidelines, institution specific order 
sets, national guidelines, utilize the hospital antibiogram, UpToDate, etc.) 
 
 
• If hospital-specific guidelines or an antibiogram, ask provider to 
demonstrate how the information is accessed  (e.g. pocket cards, online, 
etc.)  
 
• When was the last time provider accessed guidelines or received education 
regarding antimicrobial therapy?   
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5) How do you determine a definitive antimicrobial regimen (including duration) for your 
patients diagnosed with a microbiologically confirmed infection?  
(Examples could include: institution specific clinical guidelines, national guidelines, 
UpToDate, etc., duration’ response may be based on clinical improvement) 
  
 
6) [If not addressed above] Does your hospital have hospital-specific guidelines for any 
common infections? ☐ yes ☐ no  
a. If YES, can you please demonstrate where to find them?  
 
7) Does your hospital implement any specific antimicrobial stewardship (AS) interventions? 
(preauthorization, prospective audit and feedback? Infection-specific order sets? 
Diagnostic stewardship) ☐ yes ☐ no  
a. Can you specify interventions or give examples of previous interventions? 
 
8) Who do you contact to ask questions regarding antimicrobial prescribing? (Examples 
could include floor pharmacists, ASP, colleagues.)  
a. How would you contact these individuals? 
 




10) Do you receive education from your hospital regarding antimicrobial stewardship and the 
optimization of antibiotics?  ☐ yes ☐ no 
 
11) If answer to #10 is YES, how is education delivered? (Examples: prospective audit and 
feedback? Handshake stewardship? Rounding? Newsletters? One on one consult with 
ASP team or with stewardship pharmacist or ID physician? Lectures? Electronic chart 
updates?)  
 
12) What education do you provide the patient when starting them/discharging them on an 
antimicrobial? (Examples: adverse reactions, antibiotic resistance, optimal prescribing; 
verbal education, handouts, posters; assessment of patient understanding?)  
 
Tracking and Reporting: 
 
13) Do you receive data regarding antimicrobial prescribing at your hospital? ☐ yes ☐ no  
14) If answer to #13 is YES, what type of data? (Examples: antibiotic utilization, duration of 
antibiotic therapy; outcomes measurements- e.g. resistance patterns, C. difficile infection 
rates impact of AMS interventions) 
 
 
How is data delivered and in what format? (provider specific, service-line specific, 
hospital-wide) 
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Infection Specific Questions- Pneumonia  
Dx:  
Patient tracer (medical record): 
1) Orders placed from order set? ☐ yes ☐ no 
2) How did you determine patient’s severity of pneumonia? 
3) Is the following documented in the patient chart? 
• Diagnostic criteria documented?  
One or more major criterion OR ≥ three minor criterion 
Major criteria 
☐ Septic shock with need for vasopressors 
☐ Respiratory failure requiring mechanical ventilation 
Minor criteria 
☐ Respiratory rate ≥ 30 breaths/min  
 
             ☐ PaO2/FIO2 ratio ≤ 250 
☐ Multilobar infiltrates 
☐ Confusion/disorientation 
☐ Uremia (blood urea nitrogen level ≥ 20mg/dl)  
☐ Leukopenia (r/t infection alone) (white blood cell count < 4,000 cells/μl)  
☐ Thrombocytopenia (platelet count < 100,000/ μl) 
☐ Hypothermia (core temp < 36°C)  
☐ Hypotension requiring aggressive fluid resuscitation  
 
 
Classified as Severe Pneumonia ☐  
Classified as Non-severe Pneumonia ☐ 
 
4) Did you decide or verify if the patient has risk factors for MRSA, P. aeruginosa, or other 
MDROs?  
 ☐ yes ☐ no  
 
If YES, how? 
☐ prior isolation of P. aeruginosa 
☐ prior isolation of MRSA 
☐ recent hospitalization and exposure to parenteral antibiotics 
☐ arrived from facility with known MDROs 
   
5) Pretreatment gram stain and culture of lower respiratory secretions ordered?  
 ☐ yes ☐ no  
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If YES, how did you determine if sputum culture should be ordered? 
☐ classified as severe CAP (especially if intubated) 
☐ being empirically treated for MRSA or P. aeruginosa 
☐ previous infection with MRSA or P. aeruginosa (especially prior respiratory 
infection)  
☐ hospitalized and received parenteral antibiotics (during hospitalization or not)  
in last 90 days 
☐ arrived from facility with known MDROs 
 
Non-Severe Pneumonia 
1) How did you decide on your treatment for non-severe CAP? 
 
2) Standard empiric treatment for non-severe CAP used? ☐ yes ☐ no 
If YES, antibiotic therapy prescribed:  
For non-severe CAP without MRSA or P. aeruginosa risk factors:  
☐ Combination therapy with β-Lactam (ceftriaxone 1 -2g daily) and a 
macrolide (azithromycin 500 mg daily) 
☐ Monotherapy with a respiratory fluoroquinolone (levofloxacin 750 mg 
daily) (less preferred due to FQN safety issues; use if beta-lactam to be 
avoided) 
☐ β-Lactam (see above) and doxycycline 100 mg twice  
☐ none 
For non-severe CAP with MRSA or P. aeruginosa risk factors:  
☐ Empiric therapy for MRSA: vancomycin 15mg/kg q 12 hours and β-
Lactam (ceftriaxone 1-2g daily) and macrolide (azithromycin 500 mg 
daily) or doxycycline 100mg bid 
☐ Empiric therapy for P. aeruginosa: piperacillin-tazobactam 4.5g q 6 or 
q 8 hours or cefepime 2g q 8 hours or aztreonam 2g q 8 hours (only for 
severe β-Lactam allergies), or meropenem 1g q 8 hours and macrolide 
(azithromycin 500 mg daily); or doxycycline 100 mg q12 hours 
☐ none of the above 
 
3) Is Vancomycin to be administered? ☐ yes ☐ no 
a. If YES, was MRSA PCR ordered? ☐ yes ☐ no 
b. If YES, was MRSA PCR collected prior to Vancomycin administration or within 
24 hours of first dose? ☐ yes ☐ no 
4)  If PCR negative, was Vancomycin discontinued? ☐ yes ☐ no 
If NO, why? 
 
5) If PCR positive, Vancomycin continued? ☐ yes ☐ no 
If YES, why? 
6) If patient being treated for P. aeruginosa, was sputum culture ordered? ☐ yes ☐ no 
a. If YES, was sputum culture collected prior to antibiotic initiation? ☐ yes ☐ no 
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7) Did provider adjust antibiotics based on culture results? ☐ yes ☐ no 
 
Severe Pneumonia 
1) How did you decide on your treatment for severe CAP? 
 
2) Standard empiric treatment for severe CAP used? ☐ yes ☐ no  
If YES, antibiotic therapy prescribed:  
For severe CAP without MRSA or P. aeruginosa risk factors:  
☐ Combination therapy with β-Lactam (ceftriaxone 1 -2g daily) and a 
macrolide (azithromycin 500 mg daily) 
  ☐ β-Lactam/fluoroquinolone 
☐ β-Lactam (see above) and doxycycline 100 mg twice daily 
  ☐ none of the above 
For severe CAP with MRSA or P. aeruginosa risk factors:  
☐ Empiric therapy for MRSA: vancomycin 15mg/kg q 12 hours and β-
Lactam (ceftriaxone 1-2g daily) and macrolide (azithromycin 500 mg 
daily) 
☐ Empiric therapy for P. aeruginosa: piperacillin-tazobactam 4.5g q 6 or 
q 8 hours or cefepime 2g q 8 hours or aztreonam 2g q 8 hours (only for 
severe β-Lactam allergies), or meropenem 1g q 8 hours and macrolide 
(azithromycin 500 mg daily) or doxycycline 100 mg q12 hours 
☐ none of the above 
 
6) Is Vancomycin to be administered? ☐ yes ☐ no 
a. If YES, was MRSA PCR ordered? ☐ yes ☐ no 
b. If YES, was MRSA PCR collected prior to Vancomycin administration or within 
24 hours of first dose? ☐ yes ☐ no 
7) If PCR negative, was Vancomycin discontinued? ☐ yes ☐ no 
If NO, why? 
 
8) If PCR positive, Vancomycin continued? ☐ yes ☐ no 
If YES, why? 
  
9) If patient being treated for P. aeruginosa, was sputum culture ordered? ☐ yes ☐ no 
a. If YES, was sputum culture collected prior to antibiotic initiation? ☐ yes ☐ no 
 












1) Patient tested for influenza? ☐ yes ☐ no 
2) Patient urine tested for Legionella antigen? ☐ yes ☐ no  
3) Patient urine tested for pneumococcal antigen? ☐ yes ☐ no 
4) Serum procalcitonin level ordered prior to initiation of antibiotics or prior to second 
dose of antibiotics? ☐ yes ☐ no  
5) Aspiration pneumonia? ☐ yes ☐ no 
a. If YES, additional anaerobic coverage beyond standard empiric treatment for CAP?    
    ☐ yes ☐ no 
a.  If YES, is a lung abscess or empyema suspected? ☐ yes ☐ no 
Note: Metronidazole is most commonly used for anaerobic coverage. Meropenem and 
piperacillin-tazobactam also have anaerobic coverage.  
 
6) Does antibiotic order include: 
☐ indication 
☐ expected duration 
 
7) Documentation for antibiotic timeout (if done at this institution, remember terminology 
is hospital specific, what terminology is used? Handshake stewardship? Rounds?) 
☐ Will infection respond to antibiotics? 
☐ Have proper cultures and diagnostic tests been performed? (sputum culture, blood 
culture; possible diagnostic tests: pneumococcal urinary antigen, legionella urinary 
antigen, influenza during season, MRSA screen by PCR) 
☐ Can antibiotics be stopped or improved by narrowing spectrum or changing from IV 
to oral? (de-escalation) 
☐ Duration of therapy (hospital stay + post-discharge therapy) 
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For nurses:  
Action: 
1) Prior to today were aware that your hospital has an antimicrobial stewardship program 
(ASP)?  
☐ yes ☐ no ☐ unsure 
2) If YES to #1, do you know who the ASP leaders are at your hospital/institution? 
 ☐ yes ☐ no 
3) Are you provided with education regarding appropriate indications to obtain cultures? 
☐ yes ☐ no  
4) Are you provided with education regarding proper specimen collection techniques to 
reduce contamination? ☐ yes ☐ no  
5) Are you provided with education regarding antibiotic resistance and adverse reactions 
from antibiotics? ☐ yes ☐ no  
6) Are you comfortable initiating discussions with patients’ care teams regarding the 
transition from IV to oral antibiotics when the patient is able to tolerate oral medication? 
☐ yes ☐ no 
7) Are you comfortable prompting antibiotic reviews with patients’ care teams? 
☐ yes ☐ no  
If YES, when is it appropriate to initiate such reviews? 
 
8) Does your facility have specific interventions to ensure optimal use of antibiotics for 
treating the most common infections in hospitals? (e.g. ensuring correct discharge 
duration of therapy?) ☐ yes ☐ no  
9) If answer to #6 is YES, can you provide examples?    
 
Education 
10) Do you receive education from your hospital regarding antimicrobial stewardship and the 
optimization of antibiotics? ☐ yes ☐ no 
11) If answer to #10 is YES, how is education delivered? (Newsletters? Lectures? Electronic 
chart updates?)  
 
12) What education do you provide the patient when starting them/discharging them on an 
antimicrobial? (adverse reactions, antibiotic resistance, optimal prescribing; verbal 
education, handouts; posters; assessment of patient understanding?)  
 
13) Are nurses involved in creating educational materials at your hospital? 
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Tracking and Reporting: 
 
14) Do you receive data regarding antimicrobial prescribing at your hospital? ☐ yes ☐ no 
 
15) If answer to #14 is YES, what type of data? (antibiotic prescribing utilization; outcomes 
measurements- e.g. resistance patterns, C. difficile; impact of ASP interventions) 
 
a.  How is data delivered and in what format? (provider specific, service-line 
specific, hospital-wide) 
 
Patient Specific Questions: 
16) Are you aware of risk factors for MRSA? ☐ yes ☐ no 
a. If YES, is this patient at risk for MRSA? ☐ yes ☐ no ☐ don’t know 
b. If YES, was a nasal PCR collected? ☐ yes ☐ no 
c. If YES, has the final result been reviewed? ☐ yes ☐ no ☐ not available 
17) Are you aware of risk factors for P. aeruginosa? ☐ yes ☐ no 
a. If YES, do you know if this patient is at risk for P. aeruginosa 
 ☐ yes ☐ no ☐ don’t know  
b. If YES, was a sputum sample collected? ☐ yes ☐ no 
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For clinical pharmacists:  
 
Action: 
1) Do you think you have adequate knowledge of the treatment of pneumonia to evaluate 
empiric antibiotic therapy? 
☐ yes ☐ no 
2) What resources do you use when evaluating whether a chosen antimicrobial therapy is 
appropriate?  
 
3) Do you have specific experience with antibiotic stewardships? 
☐ yes ☐ no 
 
4) Does your hospital have a pharmacist(s) responsible for leading implementation efforts to 
improve antibiotic use? 
☐ yes ☐ no 
 
5) Does your hospital pharmacy have a process in place to review antibiotics prescribed? 
☐ yes ☐ no 
6) If answer to #5 is YES, is this done/documented within 48-72 hours of initiation of 
antibiotic therapy? 
Does the process include the following? 
☐ Review for dose adjustments as needed? (e.g. in cases of organ dysfunction or 
therapeutic drug monitoring)  
☐ Review for dose optimization (e.g. in cases of extended-infusion 
administration of beta-lactams in critically-ill patients and those infected with 
drug-resistant organisms) 
☐ Alerts for duplicative therapies (e.g. simultaneous use of multiple agents with 
overlapping spectra)  
☐ Automatic changes from intravenous to oral antibiotic therapy  
☐ Time-sensitive automatic stop orders  
☐ Detection and prevention of antibiotic-related drug-drug interactions  
Education: 
7) Do you receive specific education/training regarding antibiotic stewardship at your 
hospital? ☐ yes ☐ no 
8) IF answer to #7 is YES, how is education/training delivered? (posters, formal training, 
certificate program?)  
9) Do you receive data regarding antimicrobial prescribing at your hospital? ☐ yes ☐ no 
10) If answer to #9 is YES, what type of data is shared? (rate of antibiotic prescribing; 
outcomes measurements- e.g. resistance patterns, C. difficile; impact of ASP 
interventions)   
 
a.  How is data delivered and in what format? (provider specific, service-line 
specific, hospital-wide)  
 




11) Did you decide or verify if the patient has risk factors for MRSA, P. aeruginosa, or other 
MDROs? 
 ☐ yes ☐ no  
 
If YES, what criteria did you use? 
☐ prior isolation of P. aeruginosa 
☐ prior isolation of MRSA 
☐ recent hospitalization and exposure to parenteral antibiotics 
☐ arrived from facility with known MDROs 
 
12) Is Vancomycin to be administered? ☐ yes ☐ no 
a. If YES, was MRSA PCR ordered? ☐ yes ☐ no 
b. If YES, was MRSA PCR collected prior to Vancomycin administration or within 
24 hours of first dose? ☐ yes ☐ no 
c. If YES, has the final result been reviewed? ☐ yes ☐ no ☐ not available 
d. If PCR negative, was Vancomycin discontinued? ☐ yes ☐ no 
If NO, why? 
 
e. If PCR positive, Vancomycin continued? ☐ yes ☐ no 
Is YES, why? 
 
13) Is patient being treated for P. aeruginosa? ☐ yes ☐ no 
a. If YES, was sputum culture ordered? ☐ yes ☐ no 
b. If YES, was sputum culture collected prior to antibiotic initiation? ☐ yes ☐ no 
c. If YES, has the final result been reviewed? ☐ yes ☐ no ☐ not available 
 
14) On calendar day three, was antibiotic therapy discussed? ☐ yes ☐ no 
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-Problem Identification: ASP 
evaluation 
-Review/appraisal of evidence 
-Develop tracer 
-Present process of implementing 
tracer 
-Provide guidelines to implement 
and sustain tracer within system  
-Initiate tracer team meetings via face to face meetings 
and Skype 
-Create tracer with input feedback from stakeholders 
-Establish relationships with key stakeholders 
-Introduce tracer project to staff via email 
-Explain reason for tracer to leadership and clinical staff 
as needed during rounds or tracer 
-Conduct tracer interviews with hospitalists, 
pharmacists, nurses in person and via telephone 
-Present tracer findings to ASP team, hospita l 
leadership, and staff 
-Establish understanding of organizational 
priorities 
-Establish understanding of accreditation 
requirements 
-Establish understanding of influence and 











-Help novice establish access to 
EMR and contact with clinical staff 
to implement tracer 
-Orient/onboard novice 
 
-Facilitate communication between novice facilitator 
and leadership/management via face to face meetings 
and email 
-Positively promote the innovation to 
stakeholders 
-Provide formal and informal leadership 







-Provide feedback/mentoring to 
novice during tracer development 
-Review final draft of tracer prior to 
implementation 
-Aid in refining and improving 
tracer as needed 
-Evaluate final outcome of tracer 
-Facilitate integration of tracer 
methodology into future evaluation 
process 
 
-Facilitate communication between novice facilitator 
and leadership/management via face to face meetings 
and email 
-Introduce innovation to hospital leadership 
-Integrate innovation into ASP 
-Facilitate the communication of results to 
leadership and staff 
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Appendix J 
Budget and Break-Even Analysis 
Year One      
      









Hourly Rate  
Total 
Cost 
Medical Director of Pharmacy  
and Infectious Disease 
NA 20 $210,000 $101 $2,019 
Clinical Coordinator Pharmacist,  
Formulary Management and Clinical Practice 
NA 20 $136,000 $65 $1,308 
DNP student if paid 0.13 NA $98,000 $47 $12,740 
    Total Cost $16,067 
    
# of patients to  
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Appendix K 
Statement of Non-Research Determination 
 
Doctor of Nursing Practice 
Statement of Non-Research Determination (SOD) Form 
 
The SOD should be completed in NURS 7005 and NURS 791E/P or NURS 749/A/E 
General Information 
Last Name: Smyth  First Name: Christine 
     
CWID Number:   Semester/Year: Spring 2020 
     
Course Name & 
Number: 
NURS 749B 
     
Chairperson 
Name: 
  Advisor Name: Dr. Wanda Borges 
 
Project Description 
1. Title of Project 
Utilizing Tracer Methodology to Evaluate the Effectiveness of a Hospital Antimicrobial Stewardship 
Program  
2. Brief Description of Project 
Clearly state the purpose of  the project and the problem statement in 250 words or less. 
The purpose of the project is to evaluate the success of a hospital antibiotic stewardship program, identify 
potential gaps in knowledge or deviations from evidence-based practices, and verify the fulfillment of 
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3. AIM Statement: What are you trying to accomplish?  
 
The goal of  this project is to utilize tracer methodology to assess the ef fectiveness of  a hospital antibiotic 
stewardship interventions by August 2020, through the evaluation of  healthcare providers’ awareness of  antibiotic 
stewardship within their institution, knowledge regarding antimicrobial stewardship components, and approach to 
treating patients with community acquired pneumonia (CAP). 
 
4 Brief Description of Intervention (150 words). 
 4a. How will this intervention be implemented?  
• Where will you implement the project?  
• Attach a letter f rom the agency with approval of  your project.  
• Who is the focus of the intervention? 
• How will you inform stakeholders/participants about the project and the intervention? 
 
5. Outcome measurements: How will you know that a change is an improvement?   
• Measurement over time is essential to QI. Measures can be outcome, process, or balancing measures. 
Baseline or benchmark data are needed to show improvement.  
• Align your measure with your problem statement and aim.  
• Try to def ine your measure as a numerator/denominator. 
o What is the reliability and validity of  the measure? Provide any tools that you will use as 
appendices. 
o Describe how you will protect participant conf identiality.  
 
 
Using the developed tracer, the outcome measures will include physician and APP knowledge of 
hospital ASP; nurse knowledge of hospital ASP; clinical pharmacist knowledge of hospital ASP; 
physician and APP self-reported confidence regarding pneumonia treatment; and compliance 
with ATS treatment guidelines for CAP 
 
 
The intervention begins with developing a tracer based on the CDC’s Core Elements of Hospital 
Antibiotic Stewardship Programs: 2019, TJC’s New Antimicrobial Stewardship Standards, and the 
American Thoracic Society’s guidelines for diagnosing and treating adults with CAP. The tracer will 
then be conducted in a hospital setting by reviewing the charts of at least 30 patients diagnosed with CAP 
and interviewing physicians, APPs, clinical pharmacists, and nurses involved in the patient’s care. The results 
of the tracer will be analyzed and reported to the hospital antimicrobial stewardship program for the  
The tracer will be conducted at Eden Medical Center. The focus of the intervention is to evaluate the 
hospital Antibiotic Stewardship Program by interviewing hospitalists, APPs, clinical pharmacists, and nurse 
practitioners caring for patients with CAP and reviewing the EMR of patients being treated for CAP.  
Stakeholders of the project intervention will be informed via email and face to face meetings (attending 
patient rounds, ASP meetings) 




DNP Statement of Determination  
Evidence-Based Change of Practice Project Checklist* 
The SOD should be completed in NURS 7005 and NURS 791E/P or NURS 749/A/E 
 
Project Title: 
Utilizing Tracer Methodology to Evaluate the Ef fectiveness of  a Hospital Antibiotic S tewardship Program 
 
 
Mark an “X” under “Yes” or “No” for each of the following statements: Yes No 
The aim of  the project is to improve the process or delivery of  care with established/ accepted 
standards, or to implement evidence-based change. There is no intention of  using the data for 
research purposes. 
X  
The specif ic aim is to improve performance on a specif ic service or program and is a part of 
usual care. All participants will receive standard of  care. 
X  
The project is not designed to follow a research design, e.g., hypothesis testing or group 
comparison, randomization, control groups, prospective comparison groups, cross -sectional, case 
control). The project does not follow a protocol that overrides clinical decision-making. 
X  
The project involves implementation of  established and tested quality standards and/or systematic 
monitoring, assessment or evaluation of  the organization to ensure that existing quality standards 
are being met. The project does not develop paradigms or untested methods or new untested 
standards. 
X  
The project involves implementation of  care practices and interventions that are consensus -based 
or evidence-based. The project does not seek to test an intervention that is beyond current 
science and experience. 
X  
The project is conducted by staf f where the project will take place and involves staf f  who are 
working at an agency that has an agreement with USF SONHP. 
X  
The project has no funding f rom federal agencies or research-focused organizations and is not 
receiving funding for implementation research. 
X  
The agency or clinical practice unit agrees that this is a project that will be implemented to 
improve the process or delivery of  care, i.e., not a personal research project that is dependent 
upon the voluntary participation of  colleagues, students and/ or patients.  
X  
If  there is an intent to, or possibility of publishing your work, you and supervising faculty and the 
agency oversight committee are comfortable with the following statement in your methods section: 
“This project was undertaken as an Evidence-based change of practice project at X hospital or 
agency and as such was not formally supervised by the Institutional Review Board.”  
X  
 
Answer Key:  
• If  the answer to all of  these items is “Yes”, the project can be considered an evidence-based activity that does 
not meet the def inition of research. IRB review is not required. Keep a copy of this checklist in your files.  
• If  the answer to any of  these questions is “No”, you must submit for IRB approval.  
 
*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human Research Committee, Partners 
Health System, Boston, MA.   
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To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the criteria outlined in 




DNP Statement of Determination  
Evidence-Based Change of Practice Project Checklist Outcome 
The SOD should be completed in NURS 7005 and NURS 791E/P or NURS 749/A/E 
 
Project Title: 
Utilizing Tracer Methodology to Evaluate the Ef fectiveness of  a Hospital Antibiotic Stewardship Program  
 
 
X This project meets the guidelines for an Evidence-based Change in Practice Project as outlined in the Project 
Checklist (attached). Student may proceed with implementation. 
☐ This project involves research with human subjects and must be submitted for IRB approval before project 









Smyth  Student 
First Name: 
Christine 
     












Wanda Borges    
Chairperson 






DNP SOD Review 
Committee 
Member Name: 
Francine Seraf in-Dickson    
 
DNP SOD Review 
Committee 
Member 
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Presented to Medical Director of Pharmacy 
and Infection Control and Clinical 
Coordinator Pharmacist (members of tracer 
development team) 
Shared 9/10/2020 
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Appendix M 





Presented to System Regional Antimicrobial 
Stewardship Committee 
Presented 9/21/2020 
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